CureVac NV: A Positive Turn in Patent Litigation

In a significant development for CureVac NV, the biopharmaceutical company based in Tübingen, Germany, has received another favorable decision regarding the validity of its patents from the European Patent Office (EPO). This decision comes amidst an ongoing legal dispute with BioNTech SE, a prominent player in the biotech industry. The news, reported on May 15, 2025, highlights a crucial victory for CureVac as it continues to defend its intellectual property rights.

CureVac, listed on the Frankfurt Stock Exchange, specializes in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company’s focus on innovative healthcare solutions has positioned it as a key player in the global biopharmaceutical sector. However, the legal battle with BioNTech SE has been a significant challenge, with both companies vying for control over critical patent rights.

The EPO’s recent decision largely dismisses the opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023. This opposition challenged the validity of EP 4 023 755 B1, a patent held by CureVac. The EPO has maintained the patent, subject to amendments to specific claims. Additionally, a hearing on the infringement of EP 4 023 755 B1, which will also include EP 3 708 668 B1, is scheduled for later this year. The validity of EP 3 708 668 B1 was confirmed in an amended form in March 2025.

This positive outcome for CureVac could have significant implications for its market position and financial performance. As of May 13, 2025, CureVac’s stock was trading at 3.02 EUR, with a 52-week high of 4.948 EUR and a low of 2.15 EUR. The company’s market capitalization stands at approximately 702 million EUR, reflecting its standing in the healthcare sector.

The ongoing litigation and its outcomes are closely watched by investors and industry analysts, as they could influence CureVac’s strategic direction and competitive edge. The company’s ability to protect its patents is crucial for its continued innovation and growth in the rapidly evolving biopharmaceutical landscape.

As CureVac navigates these legal challenges, the broader market remains attentive to developments in the healthcare sector. Meanwhile, other financial news, such as Deutsche Bank’s plans to launch a second share buyback program, continues to shape the economic landscape in Europe.

CureVac’s journey through this legal battle underscores the importance of intellectual property in the biotech industry and the potential impact of patent decisions on a company’s future. As the situation unfolds, stakeholders will be keenly observing the next steps for CureVac and its competitors in this high-stakes arena.